New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender

NEXT STORY
Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
PREV STORY
The rapid diagnostics market by revenue is expected to grow at a CAGR of 10% during the period 2019–2025
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

Chicago, IL, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty ...

author_avatar
NASDAQ Market News

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery

MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...

author_avatar
NASDAQ Market News

Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021

author_avatar
NASDAQ Market News